Document ID: chunk:federal_register_of_legislation:F2024L00213:reg:8:p1
Version: federal_register_of_legislation:F2024L00213
Segment Type: reg
Provision Reference: reg 8 (pt 1/2)
Character Range: 3236–7015

8               Factors that must exist
At least one of the following factors must as a minimum exist before it can be said that a reasonable hypothesis has been raised connecting myocarditis or death from myocarditis with the circumstances of a person's relevant service:
(1)          undergoing a course of radiotherapy for cancer, where the heart was in the field of radiation, before clinical onset or clinical worsening;
(2)          having a myocardial infection at the time of clinical onset or clinical worsening;
(3)          having a systemic viral infection within the 4 weeks before clinical onset or clinical worsening;
(4)          being infected with human immunodeficiency virus before clinical onset or clinical worsening;
(5)          having tuberculosis before clinical onset or clinical worsening;
(6)          having acute rheumatic fever at the time of clinical onset or clinical worsening;
(7)          having one of the following vasculitides:
(a)          Behcet disease;
(b)          eosinophilic granulomatosis with polyangiitis (Churg Strauss syndrome);
(c)          giant cell (temporal) arteritis;
(d)          granulomatosis with polyangiitis (Wegener granulomatosis);
(e)          Kawasaki disease;
(f)           polyarteritis nodosa; or
(g)          Takayasu arteritis;
at the time of clinical onset or clinical worsening;
(8)          having one of the following systemic inflammatory diseases:
(a)          antiphospholipid syndrome;
(b)          coeliac disease;
(c)          dermatomyositis;
(d)          Graves disease;
(e)          Hashimoto disease;
(f)           IgG4-related disease;
(g)          inflammatory bowel disease;
(h)          mixed connective tissue disease;
(i)            polymyositis;
(j)            psoriatic arthritis;
(k)          rheumatoid arthritis;
(l)            scleroderma (progressive systemic sclerosis);
(m)        Sjögren syndrome; or
(n)          systemic lupus erythematosus;
at the time of clinical onset or clinical worsening;
(9)          having acute pancreatitis at the time of clinical onset or clinical worsening;
(10)      having myasthenia gravis at the time of or before clinical onset or clinical worsening;
(11)      having cardiac graft acute cellular rejection at the time of  clinical onset;
(12)      having a haematopoietic stem cell transplant within the 4 years before clinical onset or clinical worsening;
(13)      having a phaeochromocytoma or thymoma at the time of clinical onset or clinical worsening;
(14)      being treated with one of the following medications within the 3 months before clinical onset or clinical worsening:
(a)          alkylating agents including cyclophosphamide;
(b)          anthracyclines including doxorubicin, daunorubicin, idarubicin, epirubicin and mitoxantrone;
(c)          antibiotics including penicillin, cephalosporins, tetracyclines, sulphonamides, isoniazid, and streptomycin;
(d)          carbamazepine;
(e)          diuretics including furosemide and thiazides;
(f)           dobutamine;
(g)          dopamine;
(h)          fluoropyrimidines including 5-fluorouracil and capecitabine;
(i)            immune checkpoint inhibitors including atezolizumab, avelumab, cemiplimab, dostarlimab, durvalumab, ipilimumab, nivolumab, pembrolizumab, relatilimab, retifanlimab, and tremelimumab;
(j)            mesalazine (5-aminosalicylic acid);
(k)          methyl dopa;
(l)            paracetamol poisoning;
(m)        phenytoin;
(n)          quetiapine;
(o)          tricyclic antidepressants;
(p)          tumour necrosis factor alpha antagonists including infliximab;
(15)      being treated with clozapine within the 2 years before clinical onset or clinical worsening;
(16)      taking a medication for at least 7 days which is associated in the